VERU INC. - COMMON STOCK

Veru to Participate in Fireside Chat at the Jefferies Healthcare Conference on June 8, 2022

25 May 2022 08:30:00 By Nasdaq GlobeNewswire

Veru Announces Appointment of Joel Batten to Lead U.S. Infectious Disease Franchise to Focus on Hospitalized COVID-19 Patients

18 May 2022 08:30:01 By Nasdaq GlobeNewswire

Veru to Present at the H.C. Wainwright Global Investment Conference on May 24th 2022

17 May 2022 08:30:01 By Nasdaq GlobeNewswire

Veru Reports Second Quarter Fiscal 2022 Results and Progress of Sabizabulin for COVID-19 Toward a Request for Emergency Use Authorization

12 May 2022 06:30:00 By Nasdaq GlobeNewswire

FDA States that Veru Should Submit Request for Emergency Use Authorization (EUA) Based on Positive Efficacy and Safety Data from the Phase 3 Clinical Study of Sabizabulin in Hospitalized COVID-19 Patients

11 May 2022 06:30:00 By Nasdaq GlobeNewswire

FDA Has Granted Veru a Pre-Emergency Use Authorization (EUA) Meeting Date for Positive Sabizabulin Phase 3 COVID-19 Study

02 May 2022 08:30:00 By Nasdaq GlobeNewswire

Veru to Report Fiscal 2022 Second-Quarter Financial Results, Host Conference Call on May 12th

28 Apr 2022 08:30:01 By Nasdaq GlobeNewswire

Veru Announces Oral Late-Breaking Presentation of Phase 2 Data of Sabizabulin for the Treatment of Hospitalized Severe COVID-19 Patients at High Risk for Acute Respiratory Distress Syndrome at the 32nd European Congress of Clinical Microbiology & Infectious Diseases

25 Apr 2022 08:30:00 By Nasdaq GlobeNewswire

Veru’s Novel COVID-19 Drug Candidate Reduces Deaths by 55% in Hospitalized Patients in Interim Analysis of Phase 3 Study; Independent Data Monitoring Committee Halts Study Early for Overwhelming Efficacy

11 Apr 2022 06:30:00 By Nasdaq GlobeNewswire

Veru Announces Acceptance of Two Abstracts for Presentation at the 39th Miami Breast Cancer Conference

04 Mar 2022 08:30:00 By Nasdaq GlobeNewswire

Veru to Present at the Oppenheimer 32nd Annual Healthcare Conference on March 15-17, 2022

01 Mar 2022 08:30:01 By Nasdaq GlobeNewswire

Veru Announces the Presentation of Updated Data from the Phase 1b/2 Sabizabulin Study in Men with Metastatic Castration Resistant Prostate Cancer at the 2022 ASCO Genitourinary Cancers Symposium

17 Feb 2022 08:30:00 By Nasdaq GlobeNewswire

Veru Reports that Independent Data Monitoring Committee for the Phase 3 Sabizabulin COVID-19 Clinical Study Recommends Continuing Study as Planned

14 Feb 2022 08:30:00 By Nasdaq GlobeNewswire

Veru Reports First Quarter Fiscal 2022 Results as US FC2 Prescription Net Revenues Climb 27%

09 Feb 2022 06:30:00 By Nasdaq GlobeNewswire

Veru Announces FDA Grant of Fast Track Designation for Sabizabulin for the Treatment of Hospitalized COVID-19 Patients at High Risk for Acute Respiratory Distress Syndrome

31 Jan 2022 08:30:00 By Nasdaq GlobeNewswire

Veru to Report Fiscal 2022 First-Quarter Financial Results, Host Conference Call on February 9th

26 Jan 2022 08:30:00 By Nasdaq GlobeNewswire

Veru Announces FDA Grant of Fast Track Designation for Enobosarm for the Treatment of AR+ ER+ HER2- Metastatic Breast Cancer

10 Jan 2022 08:30:01 By Nasdaq GlobeNewswire

Veru to Present Corporate Update at the H.C. Wainwright BioConnect Conference on January 10-13, 2022

03 Jan 2022 08:30:00 By Nasdaq GlobeNewswire

Veru Announces FDA Approval of ENTADFI, a New Treatment for Benign Prostatic Hyperplasia

13 Dec 2021 08:30:00 By Nasdaq GlobeNewswire

Veru Announces Presentation of Preclinical Evidence Supporting the Therapeutic Benefit of Enobosarm Alone or in Synergistic Combination with a CDK4/6 Inhibitor Against Palbociclib Resistant Metastatic Breast Cancer at the 2021 San Antonio Breast Cancer Symposium

08 Dec 2021 08:00:00 By Nasdaq GlobeNewswire